Lexeo Therapeutics (LXEO) Research & Development (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Research & Development data on file, last reported at $15.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 8.55% year-over-year to $15.7 million; the trailing twelve-month figure through Mar 2026 stood at $46.1 million (down 38.93% YoY), and the FY2025 full-year result was $63.8 million, down 13.89% from the prior year.
• Research & Development held at $15.7 million in Q1 2026, from $15.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $23.4 million in Q3 2024 to a low of -$44.9 million in Q4 2023.
• A 5-year average of $11.7 million and a median of $15.7 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development tumbled 494.48% in 2023 and surged 140.89% in 2024, its largest moves.
• Tracing LXEO's Research & Development over 5 years: stood at $11.4 million in 2022, then plunged by 494.48% to -$44.9 million in 2023, then surged by 140.89% to $18.4 million in 2024, then fell by 14.54% to $15.7 million in 2025, then grew by 0.05% to $15.7 million in 2026.
• Business Quant data shows LXEO's Research & Development at $15.7 million in Q1 2026, $15.7 million in Q3 2025, and $14.7 million in Q2 2025.